Like Craig, I am concerned about the compensation package for Nader. My comment is that the BOD has asked us investors to exercise patience. I agree with that admonition and ask them to do the same. When we see an EUA or an equivalent type of approval for Leronlimab I will applaud this level of compensation! (I learned about Cytodyn from my account with Paulson. So I am familiar with biotech and other startups.)
On the positive side I have posted my pleasure and support for a number of recent actions especially the new BOD candidates by our management.